News | December 10, 2025
Lilly to invest $6 billion in Huntsville manufacturing hub
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Expands bioprocessing footprint across Asia
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
Subscribe To Our Newsletter & Stay Updated
